Altimmune’s (ALT) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Altimmune (NASDAQ:ALT) in a research report report published on Monday,Benzinga reports. They currently have a $12.00 price target on the stock. HC Wainwright also issued estimates for Altimmune’s FY2029 earnings at $1.26 EPS.

A number of other research firms have also recently weighed in on ALT. UBS Group initiated coverage on Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target for the company. Stifel Nicolaus initiated coverage on Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target for the company. Finally, William Blair initiated coverage on Altimmune in a report on Friday, February 28th. They issued a “market perform” rating for the company. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.83.

Altimmune Stock Performance

ALT opened at $5.72 on Monday. The business’s fifty day moving average is $6.74 and its two-hundred day moving average is $7.18. The company has a market cap of $440.52 million, a price-to-earnings ratio of -3.69 and a beta of 0.87. Altimmune has a one year low of $5.28 and a one year high of $11.77.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. On average, analysts predict that Altimmune will post -1.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Altimmune

Several institutional investors have recently added to or reduced their stakes in the business. Creative Planning grew its position in Altimmune by 20.5% during the third quarter. Creative Planning now owns 18,411 shares of the company’s stock valued at $113,000 after acquiring an additional 3,132 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in Altimmune by 119.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 40,705 shares of the company’s stock valued at $250,000 after acquiring an additional 22,188 shares during the period. Intech Investment Management LLC purchased a new stake in Altimmune during the third quarter valued at about $207,000. Charles Schwab Investment Management Inc. grew its position in Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after acquiring an additional 4,772 shares during the period. Finally, Larson Financial Group LLC purchased a new stake in Altimmune during the third quarter valued at about $31,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.